Zara Izadi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3289491/publications.pdf

Version: 2024-02-01

		687363	552781
27	2,090 citations	13	26
papers	citations	h-index	g-index
30	30	30	3538
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Development of a Natural Language Processing System for Extracting Rheumatoid Arthritis Outcomes From Clinical Notes Using the National Rheumatology Informatics System for Effectiveness Registry. Arthritis Care and Research, 2023, 75, 608-615.	3.4	10
2	Race, Ethnicity, and Disparities in the Risk of <scp>Endâ€Organ</scp> Lupus Manifestations Following a Systemic Lupus Erythematosus Diagnosis in a Multiethnic Cohort. Arthritis Care and Research, 2023, 75, 34-43.	3.4	13
3	Significant Gains in Rheumatoid Arthritis Quality Measures Among RISE Registry Practices. Arthritis Care and Research, 2022, 74, 219-228.	3.4	14
4	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. Annals of the Rheumatic Diseases, 2022, 81, 970-978.	0.9	49
5	SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. RMD Open, 2022, 8, e002187.	3.8	34
6	Association of Race and Ethnicity With COVIDâ€19 Outcomes in Rheumatic Disease: Data From the COVIDâ€19 Global Rheumatology Alliance Physician Registry. Arthritis and Rheumatology, 2021, 73, 374-380.	5.6	66
7	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Annals of the Rheumatic Diseases, 2021, 80, 1137-1146.	0.9	151
8	Socioeconomic Disparities in Functional Status in a National Sample of Patients With Rheumatoid Arthritis. JAMA Network Open, 2021, 4, e2119400.	5.9	29
9	Factors Associated With Hospitalization and Death After COVIDâ€19 Diagnosis Among Patients With Rheumatic Disease: An Analysis of Veterans Affairs Data. ACR Open Rheumatology, 2021, 3, 796-803.	2.1	5
10	Epidemiology and treatment of Behçet's disease in the USA: insights from the Rheumatology Informatics System for Effectiveness (RISE) Registry with a comparison with other published cohorts from endemic regions. Arthritis Research and Therapy, 2021, 23, 224.	3.5	10
11	Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals of the Rheumatic Diseases, 2021, 80, 930-942.	0.9	496
12	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Network Open, 2021, 4, e2129639.	5.9	86
13	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. Lancet Rheumatology, The, 2021, 3, e855-e864.	3.9	38
14	The Relationship Between Electronic Health Record System and Performance on Quality Measures in the American College of Rheumatology's Rheumatology Informatics System for Effectiveness (RISE) Registry: Observational Study. JMIR Medical Informatics, 2021, 9, e31186.	2.6	4
15	Three Quality Improvement Initiatives and Performance of Rheumatoid Arthritis Disease Activity Measures in Electronic Health Records: Results From an Interrupted Time Series Study. Arthritis Care and Research, 2020, 72, 283-291.	3.4	7
16	Healthâ€Related Quality of Life Measures in Adult Systemic Lupus Erythematosus. Arthritis Care and Research, 2020, 72, 577-592.	3.4	7
17	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals of the Rheumatic Diseases, 2020, 79, 859-866.	0.9	908
18	RISE registry reveals potential gaps in medication safety for new users of biologics and targeted synthetic DMARDs. Seminars in Arthritis and Rheumatism, 2020, 50, 1542-1548.	3.4	15

#	Article	IF	CITATIONS
19	Effects of Language, Insurance, and Race/Ethnicity on Measurement Properties of the PROMIS Physical Function Short Form 10a in Rheumatoid Arthritis. Arthritis Care and Research, 2019, 71, 925-935.	3.4	9
20	Gaps in Ambulatory Patient Safety for Immunosuppressive Specialty Medications. Joint Commission Journal on Quality and Patient Safety, 2019, 45, 348-357.	0.7	4
21	Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs. Seminars in Arthritis and Rheumatism, 2019, 48, 1087-1092.	3.4	37
22	Discordance of the Framingham cardiovascular risk score and the 2013 American College of Cardiology/American Heart Association risk score in systemic lupus erythematosus and rheumatoid arthritis. Clinical Rheumatology, 2018, 37, 467-474.	2.2	21
23	A Pilot Study of Use of a Software Platform for the Collection, Integration, and Visualization of Diabetes Device Data by Health Care Providers in a Multidisciplinary Pediatric Setting. Diabetes Technology and Therapeutics, 2018, 20, 806-816.	4.4	20
24	Patient-reported outcome measures for use in clinical trials of SLE: a review. Lupus Science and Medicine, 2018, 5, e000279.	2.7	32
25	Capturing a Patient-Reported Measure of Physical Function Through an Online Electronic Health Record Patient Portal in an Ambulatory Clinic: Implementation Study. JMIR Medical Informatics, 2018, 6, e31.	2.6	14
26	Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety. Rheumatology International, 2017, 37, 1611-1618.	3.0	11
27	Towards the patient-centred care of rheumatoid arthritis. Nature Reviews Rheumatology, 0, , .	8.0	O